MD20140101A2 - Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului - Google Patents

Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului Download PDF

Info

Publication number
MD20140101A2
MD20140101A2 MDA20140101A MD20140101A MD20140101A2 MD 20140101 A2 MD20140101 A2 MD 20140101A2 MD A20140101 A MDA20140101 A MD A20140101A MD 20140101 A MD20140101 A MD 20140101A MD 20140101 A2 MD20140101 A2 MD 20140101A2
Authority
MD
Moldova
Prior art keywords
clusterin
inhibitor
egfr
cancer
cancer cells
Prior art date
Application number
MDA20140101A
Other languages
English (en)
Russian (ru)
Inventor
Джиллс Бернард ТРЕМБЛИ
Элизабет ВИАУ
Марио ФИЛИОН
Original Assignee
Alethia Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc. filed Critical Alethia Biotherapeutics Inc.
Priority claimed from PCT/CA2013/000167 external-priority patent/WO2013123588A1/en
Publication of MD20140101A2 publication Critical patent/MD20140101A2/ro

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la medicină, în special la oncologie, şi poate fi utilizată pentru tratamentul cancerului.Conform invenţiei, expresia receptorului factorului de creştere epidermică (EGFR) şi fosforilarea se intensifică în celulele canceroase tratate cu anticorpi anti-clusterină. Un astfel de tratament este de asemenea însoţit de reapariţia unui fenotip epitelial al celulelor canceroase, aşa cum este ilustrat printr-o expresie crescută a E-caderinei la suprafaţa celulelor canceroase. Inhibitorii clusterinei pot astfel induce inversarea fenotipului epitelial în cel mezenchimal şi restabili sensibilitatea celulelor canceroase faţă de inhibitorii EGFR. Astfel, în prezenta invenţie sunt oferite combinaţii dintre un inhibitor al clusterinei şi un inhibitor EGFR, precum şi utilizarea acestora pentru tratamentul cancerului.
MDA20140101A 2013-02-22 2013-02-22 Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului MD20140101A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361601786P 2013-02-22 2013-02-22
PCT/CA2013/000167 WO2013123588A1 (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Publications (1)

Publication Number Publication Date
MD20140101A2 true MD20140101A2 (ro) 2015-02-28

Family

ID=52580519

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140101A MD20140101A2 (ro) 2013-02-22 2013-02-22 Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Country Status (1)

Country Link
MD (1) MD20140101A2 (ro)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Similar Documents

Publication Publication Date Title
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
BR112014020756A2 (pt) co-uso de um inibidor da clusterina com um inibidor do egfr para tratar o câncer
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
PH12015502339A1 (en) Arylquinazolines
CA2886946C (en) Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour
NZ628314A (en) Cd47 antibodies and methods of use thereof
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
NZ631197A (en) Anti sez6 antibodies and methods of use
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP3102609A4 (en) Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
MX392542B (es) Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
PH12016500753B1 (en) Antibodies specific to fcrn
EA201590747A1 (ru) Способы лечения с использованием аденовируса
NZ717399A (en) Antibodies against csf-1r
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
EA201690990A1 (ru) Способы получения ингибиторов фосфатидилинозитол-3-киназы
IN2014MN02114A (ro)
MX2015008726A (es) Deteccion fenotipica intracelular.
TR201909632T4 (tr) Nmda antagonisti ön ilaçları.

Legal Events

Date Code Title Description
FC9A Refusal of application (patent for invention)